A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable colorectal cancer

Charles D. Blanke; Nora C. Mattek; Thomas G. Deloughery; Dennis R. Koop

doi:10.1016/j.prostaglandins.2004.10.004

A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable colorectal cancer

Charles D. Blanke, Nora C. Mattek, Thomas G. Deloughery, Dennis R. Koop

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

A phase I study of fixed-dose 5-fluorouracil (FU) and leucovorin (LCV), with excalating doses of the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib, was conducted in 16 patients with advanced colorectal adenocarcinoma. At doses typically used to treat arthritis patients (100-200 mg po BID), celecoxib did not increase toxicities expected from the chemotherapy alone. 5-FU and leucovorin did not affect COX-2 inhibition by celecoxib. Preliminary data suggest it is safe to combine celecoxib with standard chemotherapeutic agents, in treatment of patients with colorectal cancer.

Original language	English (US)
Pages (from-to)	169-172
Number of pages	4
Journal	Prostaglandins and Other Lipid Mediators
Volume	75
Issue number	1-4
DOIs	https://doi.org/10.1016/j.prostaglandins.2004.10.004
State	Published - Jan 2005

Keywords

Cyclooxygenase-2 inhibition
Experimental trial

ASJC Scopus subject areas

Biochemistry
Physiology
Pharmacology
Cell Biology

Access to Document

10.1016/j.prostaglandins.2004.10.004

Cite this

@article{ed7a981c1af64a2f8fc3b2a269e99569,

title = "A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable colorectal cancer",

abstract = "A phase I study of fixed-dose 5-fluorouracil (FU) and leucovorin (LCV), with excalating doses of the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib, was conducted in 16 patients with advanced colorectal adenocarcinoma. At doses typically used to treat arthritis patients (100-200 mg po BID), celecoxib did not increase toxicities expected from the chemotherapy alone. 5-FU and leucovorin did not affect COX-2 inhibition by celecoxib. Preliminary data suggest it is safe to combine celecoxib with standard chemotherapeutic agents, in treatment of patients with colorectal cancer.",

keywords = "Cyclooxygenase-2 inhibition, Experimental trial",

author = "Blanke, {Charles D.} and Mattek, {Nora C.} and Deloughery, {Thomas G.} and Koop, {Dennis R.}",

note = "Funding Information: Grant support was received from the OHSU Cancer Institute, OrthoBiotech, and the Hale Family.",

year = "2005",

month = jan,

doi = "10.1016/j.prostaglandins.2004.10.004",

language = "English (US)",

volume = "75",

pages = "169--172",

journal = "Prostaglandins and Other Lipid Mediators",

issn = "1098-8823",

publisher = "Elsevier Inc.",

number = "1-4",

}

TY - JOUR

T1 - A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable colorectal cancer

AU - Blanke, Charles D.

AU - Mattek, Nora C.

AU - Deloughery, Thomas G.

AU - Koop, Dennis R.

N1 - Funding Information: Grant support was received from the OHSU Cancer Institute, OrthoBiotech, and the Hale Family.

PY - 2005/1

Y1 - 2005/1

N2 - A phase I study of fixed-dose 5-fluorouracil (FU) and leucovorin (LCV), with excalating doses of the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib, was conducted in 16 patients with advanced colorectal adenocarcinoma. At doses typically used to treat arthritis patients (100-200 mg po BID), celecoxib did not increase toxicities expected from the chemotherapy alone. 5-FU and leucovorin did not affect COX-2 inhibition by celecoxib. Preliminary data suggest it is safe to combine celecoxib with standard chemotherapeutic agents, in treatment of patients with colorectal cancer.

AB - A phase I study of fixed-dose 5-fluorouracil (FU) and leucovorin (LCV), with excalating doses of the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib, was conducted in 16 patients with advanced colorectal adenocarcinoma. At doses typically used to treat arthritis patients (100-200 mg po BID), celecoxib did not increase toxicities expected from the chemotherapy alone. 5-FU and leucovorin did not affect COX-2 inhibition by celecoxib. Preliminary data suggest it is safe to combine celecoxib with standard chemotherapeutic agents, in treatment of patients with colorectal cancer.

KW - Cyclooxygenase-2 inhibition

KW - Experimental trial

UR - http://www.scopus.com/inward/record.url?scp=13844264248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13844264248&partnerID=8YFLogxK

U2 - 10.1016/j.prostaglandins.2004.10.004

DO - 10.1016/j.prostaglandins.2004.10.004

M3 - Article

C2 - 15789623

AN - SCOPUS:13844264248

SN - 1098-8823

VL - 75

SP - 169

EP - 172

JO - Prostaglandins and Other Lipid Mediators

JF - Prostaglandins and Other Lipid Mediators

IS - 1-4

ER -

A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable colorectal cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this